Proteostasis Therapeutics Inc. (Nasdaq: PTI) reported positive results from three studies, PTI-428, PTI-801 and PTI-808 to treat cystic fibrosis. Shares of the biopharmaceutical more than doubled by leaping $3.79 to close at $6.14.
Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998. |
|||
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
||
|